<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font6" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font7" size="9" family="GillSans,BoldItalic" color="#000000"/>
<text top="41" left="55" width="122" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Medical Immunology 2006, 5 :1<i>Medical Immunology</i></text>
<text top="41" left="384" width="170" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.medimmunol.com/content/5/1/1</text>
<text top="756" left="503" width="51" height="10" font="font1" id="p1_t3" reading_order_no="107" segment_no="10" tag_type="text">Page 6 of 14<b>5</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="108" segment_no="11" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">bated at 4°C for 20 min, washed once (using 1 × PBS con-</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">taining 2% human AB serum and 1% pen-strep) and then</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">incubated with a second step of Goat-anti-mouse IgG<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">FITC at 1:200 for 20 min at 4°C. The cells were washed</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">twice and then analyzed on the FACS machine. Infected</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">721.221 cells that showed HLA surface expression (vary-</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">ing from 5% to 60%) were subsequently expanded,</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">stained and sorted for W6/32 positive cells. Sorted cells</text>
<text top="178" left="55" width="241" height="13" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">were expanded in DMEM complete containing 400 μ g/ml</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">G418, and aliquots were frozen. The following 721.221</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">cell lines are available: A0101, A0201, A0202, A0203,</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">A0204, A0205, A0206, A0207, A0301, A1101, A2301,</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">A2402, A2403, A2902, A3101, A3301, A6601, A6801,</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="2" tag_type="text">A6802, B0702, B0801, B1501, B1502, B1510, B2702,</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="2" tag_type="text">B2703, B2705. B2706, B3501, B3801, B3909, B39011,</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="2" tag_type="text">B4002, B4402, B4403, B5101, B5301, B5401, B5502,</text>
<text top="275" left="55" width="130" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="2" tag_type="text">B5701, C0102, C0304, C0702.</text>
<text top="298" left="55" width="110" height="10" font="font6" id="p1_t22" reading_order_no="19" segment_no="4" tag_type="title">Results and discussion</text>
<text top="310" left="55" width="238" height="9" font="font7" id="p1_t23" reading_order_no="20" segment_no="5" tag_type="title">Strategy for selection of HIV-1 specific CTL cell epitopes</text>
<text top="322" left="55" width="134" height="9" font="font7" id="p1_t24" reading_order_no="21" segment_no="5" tag_type="title">and generation of peptide pools</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">In this study, we approached the formulation of CTL tar-</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="6" tag_type="text">gets from a collection of 199 unique HIV-1 CTL epitopes</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="6" tag_type="text">retrieved from the Los Alamos HIV database [14]. The<b>Results and discussion</b></text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="6" tag_type="text">peptides were all 9mers, which is the optimal peptide<i><b>Strategy for selection of HIV-1 specific CTL cell epitopes </b></i></text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="6" tag_type="text">length for MHCI binding, and are known to elicit CTL<i><b>and generation of peptide pools</b></i></text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="6" tag_type="text">responses in one or more HIV-1-infected individuals,</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="6" tag_type="text">indicating that they are naturally processed during the</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="6" tag_type="text">course of infection. Identification of processed epitopes<a href="">[14]. The</a></text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="6" tag_type="text">eliminates one hurdle in CTL epitope-based vaccine</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="6" tag_type="text">design. Nonetheless, a successful CTL-based strategy must</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="6" tag_type="text">confront the sequence variability of HIV-1 strains and pol-</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="6" tag_type="text">ymorphism of the human MHCI molecules (HLA I). HIV-</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="6" tag_type="text">1 sequence variation largely contributes to immune eva-</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="6" tag_type="text">sion. In fact, it has been suggested that at a population</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="6" tag_type="text">level, HIV-1 variants have evolved to adapt to CTL</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="6" tag_type="text">responses [23,24]. Certainly, CTL escape variants can arise</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="6" tag_type="text">from mutations within and/or flanking HIV-1 CTL</text>
<text top="533" left="55" width="58" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="6" tag_type="text">epitopes [12].</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="8" tag_type="text">To select target epitopes less likely to escape from CTL, we</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="8" tag_type="text">first subjected representative viruses from all HIV-1 clades</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="8" tag_type="text">(Table 1) to a Shannon Entropy (H) variability analysis<a href="">s [23</a>,<a href="">24]. </a>Certainly, CTL escape variants can arise</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="8" tag_type="text">[25], thereby removing or "masking out" any residue with</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="8" tag_type="text">H &gt;1. See Additional file 1 for the resulting HIV-1 consen-<a href="">itopes [12</a>].</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="8" tag_type="text">sus proteome. All residues in the selected CTL epitopes are</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="8" tag_type="text">therefore quasi-invariant. The most proximal residue</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="8" tag_type="text">flanking the C-terminus of the CTL epitope is a determi-<a href="">able 1) </a>to a Shannon Entropy (H) variability analysis</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="8" tag_type="text">nant for cleavage by the proteasome, and mutations in<a href="">[25], ther</a>eby removing or "masking out" any residue with</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="8" tag_type="text">that residue can abrogate T cell recognition [26]. Accord-<a href="">1 for the resu</a>lting HIV-1 consen-</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="8" tag_type="text">ingly, we also excluded those CTL epitopes with a C-termi-</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="8" tag_type="text">nal flanking residue with H &gt;1. As a result, only 37 of the</text>
<text top="698" left="55" width="159" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="8" tag_type="text">199 HIV-1 CTL peptides were chosen.</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="3" tag_type="text">HLA I polymorphisms complicate development of a</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="3" tag_type="text">broadly protective CTL epitope vaccine by limiting popu-<a href="">ion [26</a>]. Accord-</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="text">lation coverage. For a given selection of CTL epitopes, the</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">population protection coverage (PPC) is given by the pro-</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">portion of cumulative phenotypic frequency (CPF) of the</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">HLA alleles restricting these epitopes. CPF can be com-</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">puted from the HLA gene and haplotype frequency in the</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">population. Using the HLA I gene and haplotype fre-</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">quency reported by Cao et al. [17] for five major American</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="3" tag_type="text">ethnicities (Black, Caucasian, Hispanic, Native American,</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="3" tag_type="text">and Asian), we developed an algorithm that first com-</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="3" tag_type="text">puted the binding of each epitope to 55 HLA I alleles and</text>
<text top="225" left="313" width="241" height="13" font="font4" id="p1_t68" reading_order_no="65" segment_no="3" tag_type="text">then selected epitope combinations providing a PPC ≥</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="3" tag_type="text">95% for all ethnic groups considered (details in support-<a href=""> [17</a>] for five major American</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="3" tag_type="text">ing methods). From this analysis, we predicted that as few</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="3" tag_type="text">as five epitopes from the 37 conserved HIV-1 specific CTL</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="3" tag_type="text">epitopes should be recognized by = 95% of the popula-</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="3" tag_type="text">tion, regardless of ethnicity. Furthermore, we identified 5-</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="3" tag_type="text">epitope combinations using only 25 of the 37 conserved</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="3" tag_type="text">HIV-1 specific CTL epitopes (Table 2). These 25 CTL</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="3" tag_type="text">epitopes were distributed as follows: POL (reverse tran-</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="3" tag_type="text">scriptase, integrase and protease), 14 epitopes; GAG, 5</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="3" tag_type="text">epitopes; ENV, 3 epitopes; and NEF, 3 epitopes. None of</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="3" tag_type="text">the epitopes were found in the five remaining protein</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="3" tag_type="text">open reading frames (ORFs) encoded by the HIV-1</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="3" tag_type="text">genome (VIF, TAT, REV, VPU/VPX, and VPR). This distri-<a href="">able 2). Th</a>ese 25 CTL</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="3" tag_type="text">bution reflects, in large part, the overall size as well as</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="3" tag_type="text">degree of conservation of the different HIV-1 ORFs. Fur-</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="3" tag_type="text">thermore, visual inspection of the relevant 3D structures</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="3" tag_type="text">reveals that these epitopes encompass residues that are</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="3" tag_type="text">important either for structural integrity and/or catalytic</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="3" tag_type="text">activity. For example, epitopes TLVDVGDAY and</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="3" tag_type="text">VIYQYMDDL from HIV-1 reverse transcriptase (POL)</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="3" tag_type="text">bear 6 and 4 residues, respectively, involved in substrate</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="3" tag_type="text">binding and catalysis [27]. The penalty for mutations at</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="3" tag_type="text">any of these sites vis-a-vis viral fitness presumably pre-</text>
<text top="510" left="313" width="189" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="3" tag_type="text">cludes ready development of escape variants.</text>
<text top="533" left="313" width="231" height="9" font="font7" id="p1_t93" reading_order_no="90" segment_no="7" tag_type="title">A minority of HIV-1 patients responds to HIV-1 specific</text>
<text top="545" left="313" width="77" height="9" font="font7" id="p1_t94" reading_order_no="91" segment_no="7" tag_type="title">CTL peptide pools</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="9" tag_type="text">That as few as 5 peptides may provide the requisite PPC</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="9" tag_type="text">largely stems from their ability to bind to many different<a href="">27]. The</a> penalty for mutations at</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="9" tag_type="text">HLA I molecules. The peptide SPRTLNAWV itself is antic-</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="9" tag_type="text">ipated to bind to eight distinct HLA I allelic variants, offer-</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="9" tag_type="text">ing a PPC ranging from 35% in Asians to 52% in North<i><b>A minority of HIV-1 patients responds to HIV-1 specific </b></i></text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="9" tag_type="text">American Indians. Such promiscuous MHCI-peptide<i><b>CTL peptide pools</b></i></text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="9" tag_type="text">binding often resides in previously defined HLA I super-</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="9" tag_type="text">types (i.e. alleles with similar peptide binding specificity</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="9" tag_type="text">[28]), e.g., the peptide SPRTLNAWV binds to the B7</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="9" tag_type="text">supertype and the peptide AVFIHNFKR to the A3 super-</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="9" tag_type="text">type. Nevertheless, binding promiscuity is not exclusively</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="9" tag_type="text">confined to HLA I supertypes. For instance, the peptide</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="9" tag_type="text">EKEGKISKI is predicted to bind to the alleles B2701,</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="9" tag_type="text">B3801 B39011, B3909, B4402, B5101 and B0801, which</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t109" reading_order_no="106" segment_no="9" tag_type="text">do not conform to any known supertype, and peptide<a href="">[28</a>]), e.g., the peptide SPRTLNAWV binds to the B7</text>
</page>
</pdf2xml>
